<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212352</url>
  </required_header>
  <id_info>
    <org_study_id>62449</org_study_id>
    <nct_id>NCT03212352</nct_id>
  </id_info>
  <brief_title>Comparing Two Medical Treatments for Early Pregnancy Failure.</brief_title>
  <acronym>Triple M</acronym>
  <official_title>Mifepristone and Misoprostol Versus Misoprostol Alone for Uterine Evacuation After Early Pregnancy Failure: a Randomized Double Blind Placebo-controlled Comparison (Triple M Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovatiefonds Zorgverzekeraars</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canisius-Wilhelmina Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare whether a combination of two drugs (Mifepristone and misoprostol)
      are superior compared to using only one of these drugs (Misoprostol) as medical treatment for
      a miscarriage. Women in whom early pregnancy failure, 6-14 weeks postmenstrual, is
      ultrasonographically confirmed qualify for this study.

      It is expected that the combination of Mifepristone and Misoprostol is more effective in
      reaching complete evacuation, and therefore can prevent more invasive treatment such as
      curettage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the hypothesis that, in early pregnancy failure, the sequential
      combination of mifepristone with misoprostol is superior to the use of misoprostol alone in
      terms of complete evacuation of products of conception (primary outcome), patient
      satisfaction, complications, side effects and costs (secondary outcomes). The trial will be
      performed multi-centred (hospitals), prospectively, two-armed, randomized, double-blinded and
      placebo-controlled.

      Women with ultrasonographically confirmed early pregnancy failure (6-14 weeks postmenstrual),
      managed expectantly for at least one week, can be included. Before medical treatment with
      misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is
      lost), patients will be randomized to oral mifepristone (600mg) or oral placebo (identical in
      appearance). The investigators aim to randomize 460 women in a 1:1 ratio, stratified by
      centre.

      After six weeks, the primary endpoint, complete or incomplete evacuation, will be determined
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients will be randomized to oral mifepristone (600mg) or oral placebo (identical in appearance).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete evacuation</measure>
    <time_frame>six weeks after initial treatment</time_frame>
    <description>Whether or not complete evacuation (total endometrial thickness &lt;15 mm) has been acquired will be assessed through ultrasonography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>At baseline, day four, two and six weeks after treatment</time_frame>
    <description>To assess how satisfied patient are with the treatment they underwent. Patient satisfaction with treatment will be measured using The Client Satisfaction Questionnaire (CSQ-8, digital)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complications</measure>
    <time_frame>six weeks after treatment</time_frame>
    <description>How many and which complications have occured?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>six weeks after treatment</time_frame>
    <description>Which side effects have patients experienced and to what degree?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>costs</measure>
    <time_frame>up to six weeks after treatment</time_frame>
    <description>To evaluate which medical treatment strategy is cost-effective, volumes of health care consumed will additionally be measured prospectively alongside the clinical trial together with cost associated with productivity losses. Costs of medical interventions (direct costs) and costs resulting from productivity loss (indirect costs) will be taken into account. Resource uses will be recorded in the case report forms. Standardized unit costs will be calculated using the Dutch manual for costing in economic evaluations and standardised costs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall quality of health, as experienced by the patient.</measure>
    <time_frame>At baseline, day four, and two and six weeks after initial treatment.</time_frame>
    <description>To measure the quality of the health status of the patients, a validated so-called health-related quality of life (HRQoL) instrument will be used: the Short Form 36 health survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall quality of health, as experienced by the patient.</measure>
    <time_frame>At baseline, day four, and two and six weeks after initial treatment.</time_frame>
    <description>To measure the quality of the health status of the patients,a validated so-called health-related quality of life (HRQoL) instrument will be used: the EuroQol-5D.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Early Pregnancy Failure</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive an oral placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Misoprostol and Mifepristone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive oral mifepristone (600mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Adding 600 mg of Mifepristone to the regular treatment with Misoprostol 800 mcg.</description>
    <arm_group_label>Misoprostol and Mifepristone</arm_group_label>
    <other_name>Mifegyne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Regular treatment with Misoprostol 800 mcg.</description>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_label>Misoprostol and Mifepristone</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Early pregnancy failure, 6-14 weeks postmenstrual with

          -  a crown-rump length â‰¥ 6mm and no cardiac activity OR

          -  a crown-rump length &lt;6mm and no fetal growth at least one week later OR

          -  a gestational sac with absent embryonic pole for at least one week.

               -  At least one week after diagnosis OR a discrepancy of at least one week between
                  crown-rump length and calendar gestational age

               -  Intra-uterine pregnancy

               -  Women aged above 16 years

               -  Hemodynamic stable patient

               -  No signs of infection

               -  No signs of incomplete abortion

               -  No contraindications for mifepristone or misoprostol

        Exclusion Criteria:

          -  Patient does not meet inclusion criteria, discovered after randomization

          -  Inability to give informed consent

          -  Known clotting disorder or use of anticoagulants

          -  Known risk factors for, or presence of, a cardiovascular disease

          -  Language barrier
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank P. Vandenbussche, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Radboud UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte C Hamel, MD</last_name>
    <phone>0031243658750</phone>
    <email>l.hamel@cwz.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcus P. Snijders, Dr.</last_name>
    <phone>0031243658750</phone>
    <email>m.snijders@cwz.nl</email>
  </overall_contact_backup>
  <link>
    <url>http://www.opendisdata.nl/</url>
    <description>open data from the Nederlandse Zorgautoriteit (Dutch Healthcare Authority)</description>
  </link>
  <link>
    <url>http://www.rcog.org.uk/</url>
    <description>The management of early pregnancy loss. Royal College of Obstetricians and Gynaecologists, Green-top Guideline No. 25.</description>
  </link>
  <link>
    <url>http://www.nvog.nl</url>
    <description>Zwangerschapsafbreking tot 24 weken. Richtlijn Nederlandse Vereniging voor Obstetrie &amp; Gynaecologie.</description>
  </link>
  <link>
    <url>http://www.medicines.org.uk/emc/medicine/9352</url>
    <description>Cytotec UK SPC (Summary of Product Characteristics).</description>
  </link>
  <link>
    <url>http://www.figo.org/publications/miscellaneous_publications/Misoprostol_Recommendation_2012</url>
    <description>Misoprostol Recommendations. International Federation of Gynecology and Obstetrics (FIGO)</description>
  </link>
  <link>
    <url>http://www.exelgyn.com</url>
    <description>Mifegyne 200 mg tablets: Summary of Product Characteristics (SmPC)</description>
  </link>
  <link>
    <url>http://www.farmacotherapeutischkompas.nl</url>
    <description>Mifepristone - Mifegyne</description>
  </link>
  <reference>
    <citation>Graziosi GC, Mol BW, Reuwer PJ, Drogtrop A, Bruinse HW. Misoprostol versus curettage in women with early pregnancy failure after initial expectant management: a randomized trial. Hum Reprod. 2004 Aug;19(8):1894-9. Epub 2004 Jun 10.</citation>
    <PMID>15192065</PMID>
  </reference>
  <reference>
    <citation>You JH, Chung TK. Expectant, medical or surgical treatment for spontaneous abortion in first trimester of pregnancy: a cost analysis. Hum Reprod. 2005 Oct;20(10):2873-8. Epub 2005 Jun 24.</citation>
    <PMID>15979988</PMID>
  </reference>
  <reference>
    <citation>Hooker AB, Lemmers M, Thurkow AL, Heymans MW, Opmeer BC, BrÃ¶lmann HA, Mol BW, Huirne JA. Systematic review and meta-analysis of intrauterine adhesions after miscarriage: prevalence, risk factors and long-term reproductive outcome. Hum Reprod Update. 2014 Mar-Apr;20(2):262-78. doi: 10.1093/humupd/dmt045. Epub 2013 Sep 29. Review.</citation>
    <PMID>24082042</PMID>
  </reference>
  <reference>
    <citation>Lemmers M, Verschoor MA, Hooker AB, Opmeer BC, Limpens J, Huirne JA, Ankum WM, Mol BW. Dilatation and curettage increases the risk of subsequent preterm birth: a systematic review and meta-analysis. Hum Reprod. 2016 Jan;31(1):34-45. doi: 10.1093/humrep/dev274. Epub 2015 Nov 2. Review.</citation>
    <PMID>26534897</PMID>
  </reference>
  <reference>
    <citation>Soulat C, Gelly M. [Immediate complications of surgical abortion]. J Gynecol Obstet Biol Reprod (Paris). 2006 Apr;35(2):157-62. Review. French.</citation>
    <PMID>16575361</PMID>
  </reference>
  <reference>
    <citation>NiinimÃ¤ki M, Jouppila P, Martikainen H, Talvensaari-Mattila A. A randomized study comparing efficacy and patient satisfaction in medical or surgical treatment of miscarriage. Fertil Steril. 2006 Aug;86(2):367-72. Epub 2006 Jun 9.</citation>
    <PMID>16764872</PMID>
  </reference>
  <reference>
    <citation>Neilson JP, Hickey M, Vazquez J. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002253. Review.</citation>
    <PMID>16855990</PMID>
  </reference>
  <reference>
    <citation>van den Berg J, Gordon BB, Snijders MP, Vandenbussche FP, Coppus SF. The added value of mifepristone to non-surgical treatment regimens for uterine evacuation in case of early pregnancy failure: a systematic review of the literature. Eur J Obstet Gynecol Reprod Biol. 2015 Dec;195:18-26. doi: 10.1016/j.ejogrb.2015.09.027. Epub 2015 Sep 30. Review.</citation>
    <PMID>26461963</PMID>
  </reference>
  <reference>
    <citation>Lemmers M, Verschoor MAC, Oude Rengerink K, Naaktgeboren C, Bossuyt PM, Huirne JAF, Janssen IAH, Radder C, Klinkert ER, Langenveld J, van der Voet L, Siemens FF, Bongers MY, van Hooff MH, van der Ploeg M, Sjors FPJ, Coppus SFPJ, Ankum WM, Mol BWJ; MisoREST study group. MisoREST: Surgical versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for miscarriage: A cohort study. Eur J Obstet Gynecol Reprod Biol. 2017 Apr;211:83-89. doi: 10.1016/j.ejogrb.2017.01.019. Epub 2017 Jan 27.</citation>
    <PMID>28209537</PMID>
  </reference>
  <reference>
    <citation>Lemmers M, Verschoor MA, Oude Rengerink K, Naaktgeboren C, Opmeer BC, Bossuyt PM, Huirne JA, Janssen CA, Radder C, Klinkert ER, Langenveld J, Catshoek R, Van der Voet L, Siemens F, Geomini P, Van Hooff MH, Van der Ploeg JM, Coppus SF, Ankum WM, Mol BW; MisoREST study group. MisoREST: surgical versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for miscarriage: a randomized controlled trial. Hum Reprod. 2016 Nov;31(11):2421-2427. Epub 2016 Sep 2.</citation>
    <PMID>27591236</PMID>
  </reference>
  <reference>
    <citation>Say L, Kulier R, GÃ¼lmezoglu M, Campana A. Medical versus surgical methods for first trimester termination of pregnancy. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003037. Review.</citation>
    <PMID>15674900</PMID>
  </reference>
  <reference>
    <citation>Kulier R, Kapp N, GÃ¼lmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD002855. doi: 10.1002/14651858.CD002855.pub4. Review.</citation>
    <PMID>22071804</PMID>
  </reference>
  <reference>
    <citation>Maria B, Chaneac M, Stampf F, Ulmann A. [Early pregnancy interruption using an antiprogesterone steroid: Mifepristone (RU 486)]. J Gynecol Obstet Biol Reprod (Paris). 1988;17(8):1089-94. French.</citation>
    <PMID>3235788</PMID>
  </reference>
  <reference>
    <citation>Grimes DA, Mishell DR Jr, Shoupe D, Lacarra M. Early abortion with a single dose of the antiprogestin RU-486. Am J Obstet Gynecol. 1988 Jun;158(6 Pt 1):1307-12.</citation>
    <PMID>2454578</PMID>
  </reference>
  <reference>
    <citation>van den Berg J, van den Bent JM, Snijders MP, de Heus R, Coppus SF, Vandenbussche FP. Sequential use of mifepristone and misoprostol in treatment of early pregnancy failure appears more effective than misoprostol alone: a retrospective study. Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:16-9. doi: 10.1016/j.ejogrb.2014.10.010. Epub 2014 Oct 14.</citation>
    <PMID>25461345</PMID>
  </reference>
  <reference>
    <citation>Stockheim D, Machtinger R, Wiser A, Dulitzky M, Soriano D, Goldenberg M, Schiff E, Seidman DS. A randomized prospective study of misoprostol or mifepristone followed by misoprostol when needed for the treatment of women with early pregnancy failure. Fertil Steril. 2006 Oct;86(4):956-60.</citation>
    <PMID>17027362</PMID>
  </reference>
  <reference>
    <citation>Wagaarachchi PT, Ashok PW, Narvekar N, Smith NC, Templeton A. Medical management of early fetal demise using a combination of mifepristone and misoprostol. Hum Reprod. 2001 Sep;16(9):1849-53.</citation>
    <PMID>11527887</PMID>
  </reference>
  <reference>
    <citation>GrÃ¸nlund A, GrÃ¸nlund L, Clevin L, Andersen B, Palmgren N, Lidegaard Ã˜. Management of missed abortion: comparison of medical treatment with either mifepristone + misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark. Acta Obstet Gynecol Scand. 2002 Nov;81(11):1060-5.</citation>
    <PMID>12421175</PMID>
  </reference>
  <reference>
    <citation>Coughlin LB, Roberts D, Haddad NG, Long A. Medical management of first trimester miscarriage (blighted ovum and missed abortion): is it effective? J Obstet Gynaecol. 2004 Jan;24(1):69-71.</citation>
    <PMID>14675986</PMID>
  </reference>
  <reference>
    <citation>Schreiber CA, Creinin MD, Reeves MF, Harwood BJ. Mifepristone and misoprostol for the treatment of early pregnancy failure: a pilot clinical trial. Contraception. 2006 Dec;74(6):458-62. Epub 2006 Sep 7.</citation>
    <PMID>17157102</PMID>
  </reference>
  <reference>
    <citation>Kollitz KM, Meyn LA, Lohr PA, Creinin MD. Mifepristone and misoprostol for early pregnancy failure: a cohort analysis. Am J Obstet Gynecol. 2011 May;204(5):386.e1-6. doi: 10.1016/j.ajog.2010.12.026. Epub 2011 Feb 8.</citation>
    <PMID>21306697</PMID>
  </reference>
  <reference>
    <citation>Torre A, Huchon C, Bussieres L, Machevin E, Camus E, Fauconnier A. Immediate versus delayed medical treatment for first-trimester miscarriage: a randomized trial. Am J Obstet Gynecol. 2012 Mar;206(3):215.e1-6. doi: 10.1016/j.ajog.2011.12.009. Epub 2011 Dec 16.</citation>
    <PMID>22381604</PMID>
  </reference>
  <reference>
    <citation>Luise C, Jermy K, May C, Costello G, Collins WP, Bourne TH. Outcome of expectant management of spontaneous first trimester miscarriage: observational study. BMJ. 2002 Apr 13;324(7342):873-5.</citation>
    <PMID>11950733</PMID>
  </reference>
  <reference>
    <citation>Rulin MC, Bornstein SG, Campbell JD. The reliability of ultrasonography in the management of spontaneous abortion, clinically thought to be complete: a prospective study. Am J Obstet Gynecol. 1993 Jan;168(1 Pt 1):12-5.</citation>
    <PMID>8420312</PMID>
  </reference>
  <reference>
    <citation>Creinin MD, Harwood B, Guido RS, Fox MC, Zhang J; NICHD Management of Early Pregnancy Failure Trial. Endometrial thickness after misoprostol use for early pregnancy failure. Int J Gynaecol Obstet. 2004 Jul;86(1):22-6.</citation>
    <PMID>15207665</PMID>
  </reference>
  <reference>
    <citation>Chung TK, Cheung LP, Sahota DS, Haines CJ, Chang AM. Evaluation of the accuracy of transvaginal sonography for the assessment of retained products of conception after spontaneous abortion. Gynecol Obstet Invest. 1998;45(3):190-3.</citation>
    <PMID>9565145</PMID>
  </reference>
  <reference>
    <citation>Jauniaux E, Johns J, Burton GJ. The role of ultrasound imaging in diagnosing and investigating early pregnancy failure. Ultrasound Obstet Gynecol. 2005 Jun;25(6):613-24. Review.</citation>
    <PMID>15861413</PMID>
  </reference>
  <reference>
    <citation>Verschoor MA, Lemmers M, Wekker MZ, Huirne JA, Goddijn M, Mol BW, Ankum WM. Practice variation in the management of first trimester miscarriage in the Netherlands: a nationwide survey. Obstet Gynecol Int. 2014;2014:387860. doi: 10.1155/2014/387860. Epub 2014 Nov 4.</citation>
    <PMID>25538770</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>miscarriage</keyword>
  <keyword>mifepristone</keyword>
  <keyword>misoprostol</keyword>
  <keyword>medical treatment</keyword>
  <keyword>patient satisfaction</keyword>
  <keyword>abortifacient agents</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>n.a.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

